Literature DB >> 31248612

Activating and inhibitory killer cell immunoglobulin like receptors (KIR) genes are involved in an increased susceptibility to colorectal adenocarcinoma and protection against invasion and metastasis.

Shaghik Barani1, Seyed Vahid Hosseini2, Abbas Ghaderi3.   

Abstract

BACKGROUND: A set of activating and inhibitory KIRs (aKIR, iKIR) are involved in NK cell mediated immunity. This study was carried out in order to investigate the KIRs pattern and its association with colorectal carcinoma (CRC) development and clinical outcomes.
METHODS: Sequence-specific primers-polymerase chain reaction (SSP-PCR) for typing of 16 KIR genes was utilized in 165 patients with colorectal adenocarcinoma with 165 age and gender matched healthy controls (CNs).
RESULTS: Possessing KIR2DS1, 2DS5, 3DS1, 2DS4fl, 2DL5, telomeric half KIR genes, ≥ 4 aKIR and CXT4 genotype were associated with an increased susceptibility to colorectal adenocarcinoma while KIR2DS4del and iKIR >aKIR confer resistance to CRC. On the other hand, clinical associations revealed the defensive role of telomeric KIR3DL1, 3DS1, 2DS1, 2DS4, genotypes with ≥ 4 aKIR and more inhibitory KIRs than activating ones (I > A) against metastasis and CXTX genotype in perineural invasion.
CONCLUSION: According to current results it appears that KIRs system play distinctive roles in development and metastasis of colorectal adenocarcinoma.
Copyright © 2019 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Colorectal adenocarcinoma; Invasion; Killer immunoglobulin like receptors (KIRs); Metastasis; NK cells; SSP-PCR

Mesh:

Substances:

Year:  2019        PMID: 31248612     DOI: 10.1016/j.imbio.2019.06.002

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  7 in total

1.  Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression.

Authors:  Tehila Azoulay; Ilana Slouzky; Michal Karmona; Margarita Filatov; Michal Hayun; Yishai Ofran; Galit Sarig; Shimrit Ringelstein-Harlev
Journal:  Cancer Immunol Immunother       Date:  2022-09-01       Impact factor: 6.630

2.  Association of killer cell immunoglobulin-like receptors with endemic Burkitt lymphoma in Kenyan children.

Authors:  Beatrice M Muriuki; Catherine S Forconi; Peter O Oluoch; Jeffrey A Bailey; Anita Ghansah; Ann M Moormann; John M Ong'echa
Journal:  Sci Rep       Date:  2021-05-31       Impact factor: 4.379

Review 3.  Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword.

Authors:  Qiutong Huang; Wang Cao; Lisa Anna Mielke; Cyril Seillet; Gabrielle T Belz; Nicolas Jacquelot
Journal:  Front Immunol       Date:  2020-01-15       Impact factor: 7.561

4.  Analysis of Killer Immunoglobulin-Like Receptor Genes in Colorectal Cancer.

Authors:  Roberto Diaz-Peña; Patricia Mondelo-Macía; Antonio José Molina de la Torre; Rebeca Sanz-Pamplona; Víctor Moreno; Vicente Martín
Journal:  Cells       Date:  2020-02-24       Impact factor: 6.600

5.  Coexistence of inhibitory and activating killer-cell immunoglobulin-like receptors to the same cognate HLA-C2 and Bw4 ligands confer breast cancer risk.

Authors:  Elham Ashouri; Karan Rajalingam; Shaghik Barani; Shirin Farjadian; Abbas Ghaderi; Raja Rajalingam
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379

6.  Molecular Profiling of Tumor Tissue in Mexican Patients with Colorectal Cancer.

Authors:  Beatriz Armida Flores-López; María de la Luz Ayala-Madrigal; José Miguel Moreno-Ortiz; Jorge Peregrina-Sandoval; Miguel Ángel Trujillo-Rojas; José Luis Venegas-Rodríguez; Rosario Hernández-Ramírez; Martha Alejandra Fernández-Galindo; Melva Gutiérrez-Angulo
Journal:  Curr Issues Mol Biol       Date:  2022-08-20       Impact factor: 2.976

7.  KIR-HLA gene diversities and susceptibility to lung cancer.

Authors:  Marjan Hematian Larki; Elham Ashouri; Shaghik Barani; Seiyed Mohammad Ali Ghayumi; Abbas Ghaderi; Raja Rajalingam
Journal:  Sci Rep       Date:  2022-10-14       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.